http://www.cnqixia.com/article/But-Ive-never-been---.html
Hematide is in a Phase III trial. Rento led Onyx for nearly 15 years, stepping down in February 2008as president, CEO, chairman and a membe of Onyx’s board. At the company, he helped negotiate a development and commercialization partnership with that resulted inthe anti-cancerf drug Nexavar. Nexavar tablets, which cost abouyt $5,000 a month in the Unitede States and areapproaching $1 billion in annual are approved in more than 80 countries to treat kidnety cancer and 70-plus countries for liver cancer. Prior to joining Renton was president and COO of which acquired Cetusin 1991. Rentonb had been president of Cetussince 1990, COO sinc e 1987 and CFO from 1983 to 1987.
Rentonm also serves on the boardsof , Cepheixd and the Special Olympics of Northern
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment